Welcome to our dedicated page for Medifast news (Ticker: MED), a resource for investors and traders seeking the latest updates and insights on Medifast stock.
Medifast, Inc. reports developments as a metabolic health and wellness company built around the OPTAVIA science-backed, coach-guided lifestyle system. Its updates center on revenue trends, gross margin, active earning coaches, coach productivity and the company's shift toward metabolic health amid changes in weight-loss demand and GLP-1 medication adoption.
Recurring company news also covers OPTAVIA program evidence, nutrition and habit-creation offerings, HSA/FSA reimbursement availability on select insurance plans, independent coach community initiatives, media content tied to metabolic health, and governance matters such as board nominations and stockholder cooperation agreements.
Medifast (NYSE: MED) premiered the second episode of its OPTAVIA docuseries, “Health by Design: Spain”, which examines factors that support metabolic health and longevity in Galicia and Madrid. The episode, hosted by OPTAVIA co-founder Dr. Wayne Andersen and President Nicholas Johnson, highlights community, routine, activity, and diet as drivers of healthspan. The premiere was celebrated by thousands of independent coaches at Get America Healthy events on January 10, 2026.
Medifast (NYSE: MED) announced a planned leadership transition: Nicholas Johnson is appointed President effective immediately and is expected to succeed Dan Chard as Chief Executive Officer in June 2026. Dan Chard will remain Chairman of the Board after stepping down as CEO. The company said Johnson will work closely with Chard and the Board during a deliberate transition period. The announcement also notes that Tony Tyree, Chief Business Operations Officer, is leaving the company effective immediately. Johnson joined Medifast in 2018 and became Chief Field Operations Officer in 2022, having previously held leadership roles at Nu Skin.
Medifast (NYSE: MED) published OPTAVIA's report "Metabolic Health in America" (survey fielded Sep 23–29, 2025; n=1,004) showing 80% of U.S. adults lack understanding of metabolic health while 94% express concern about at least one related issue.
Key survey outcomes: 43% had heard the term, 65% report three+ metabolic concerns, 74% felt motivated to improve after learning the definition, and 85% believe metabolic dysfunction can be reversed. The release links these findings to Medifast's 2025 strategic shift to Metabolic Synchronization and cites a clinical study showing 14% visceral fat reduction and 98% lean mass retained at 16 weeks.
Medifast (NYSE:MED) presented new metabolic health research at ObesityWeek in Atlanta (Nov 4–7, 2025).
Two poster studies highlighted: a GLP‑1/dual agonist analysis showing a weight‑loss plateau after 96 weeks at the highest tirzepatide dose (15 mg) and a rebound in energy intake and weight after medication discontinuation; and a sleep analysis from Midlife in the United States linking poor sleep quality to higher long‑term odds of obesity (1.8×) and diabetes (2.5×) over ~12 years. Medifast reiterated its Oct 2025 strategy launch, Metabolic Synchronization™, and emphasized lifestyle integration (nutrition, behavioral support, self‑monitoring) alongside medical therapies.
Medifast (NYSE: MED) reported third quarter 2025 results with revenue $89.4M (down 36.2% YoY) and a net loss $2.3M (loss of $0.21 per diluted share). Active earning OPTAVIA coaches fell 35.0% to 19,500, driving lower sales; revenue per active coach was $4,585. Gross profit declined 41.2% to $62.2M and gross margin narrowed to 69.5%. SG&A decreased 36.0% to $66.2M but rose slightly as a percent of revenue to 74.1%. The company ended the quarter with a strong balance sheet: $173.5M cash and investments, no debt. Guidance: Q4 2025 revenue $65M–$80M and diluted loss per share $(0.70)–(1.25).
Medifast (NYSE: MED) announced a strategic shift to focus on metabolic health with the introduction of Metabolic Synchronization™, a clinical-backed system the company says reduces visceral fat, preserves lean mass and protects muscle.
Key data: a 14% reduction in visceral fat in 16 weeks and retention of 98% of lean mass reported in company research. Medifast plans new product launches using this science in 2026 and emphasizes coach-led programs and published clinical evidence supporting the approach.
Medifast (NYSE: MED) will announce financial results for the quarter ended September 30, 2025 on Monday, November 3, 2025 after market close.
The company will host a conference call on November 3, 2025 at 4:30 p.m. ET with participants Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer.
The call will be broadcast live on the company's Investor Relations site and via webcast, archived online and available through February 3, 2026. Telephone dial-in and telephonic playback details are provided for live and replay access.
Medifast (NYSE:MED) has revealed groundbreaking findings about its Optimal Weight 5 & 1 Plan®, demonstrating significant metabolic health benefits. The study shows the plan helps preserve 98% of lean mass after 16 weeks, a crucial factor for maintaining optimal metabolic health.
The company's research is particularly relevant as 90% of U.S. adults are classified as metabolically unhealthy. Medifast's scientific foundation includes over 30 research studies, 70+ peer-reviewed abstract presentations, and 30+ peer-reviewed publications accumulated over its 40-year history.
The company plans to expand its scientific research and will host a Scientific Advisory Board meeting to explore new opportunities in addressing metabolic dysfunction.
Medifast (NYSE: MED) reported challenging second quarter 2025 results, with revenue declining 37.4% to $105.6 million from $168.6 million in Q2 2024. The company's active OPTAVIA coaches decreased 32.7% to 22,800, while revenue per coach fell to $4,630. Despite operational challenges, Medifast maintained a strong balance sheet with $162.7 million in cash and no debt.
Net income was $2.5 million ($0.22 per share), including a $2.0 million gain from LifeMD investment. The company faces headwinds from GLP-1 weight loss medications but highlighted positive clinical findings showing their OPTAVIA 5 & 1 Plan preserves 98% of lean mass. For Q3 2025, Medifast projects revenue between $70-90 million with EPS ranging from ($0.60) to $0.00.
Medifast (NYSE: MED), the company behind the OPTAVIA® health and wellness program, has scheduled its Q2 2025 financial results announcement for August 4, 2025, after market close.
The company will host a conference call at 4:30 p.m. ET featuring Chairman and CEO Dan Chard and CFO Jim Maloney. The call will be available via webcast on Medifast's Investor Relations website and will remain archived through November 3, 2025. Telephone participants can dial (201) 389-0879, with playback access available through August 11, 2025.